NRIX

Nurix Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↓ 2/10
  • Momentum↑ 7/10
Nurix Therapeutics sales and earnings growth
NRIX Growth
Fair
  • Revenue Y/Y↑ 53.95%
  • EPS Y/Y↓ -5.90%
  • FCF Y/Y↓ -44.88%
Nurix Therapeutics gross and profit margin trends
NRIX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -314.90%
  • ROIC↓ -59.10%
Nurix Therapeutics net debt vs free cash flow
NRIX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Nurix Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗